^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    KITE-718

    i
    Other names: KITE-718, KITE 718, MAGE-A3/A6 TCR transduced T cells, MAGE A3/A6
    Associations

    News

    Trials
    Company:
    Gilead
    Drug class:
    TCR modulator, MAGE-A3 modulator, MAGE-A6 modulator
    Related drugs:
    Associations

    News

    Trials
    9ms
    Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells (clinicaltrials.gov)
    P2, N=700, Enrolling by invitation, Kite, A Gilead Company | Trial completion date: Mar 2041 --> Dec 2040 | Trial primary completion date: Mar 2041 --> Dec 2040
    Trial completion date • Trial primary completion date
    |
    Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • KITE-222 • KITE-363 • KITE-439 • KITE-585 • KITE-718
    over1year
    KITE-718-301: Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=16, Terminated, Kite, A Gilead Company | Active, not recruiting --> Terminated; The study was terminated due to the sponsor's decision to discontinue the clinical trial.
    Trial termination • Metastases
    |
    HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1)
    |
    cyclophosphamide • fludarabine IV • KITE-718
    over1year
    Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells (clinicaltrials.gov)
    P2, N=700, Enrolling by invitation, Kite, A Gilead Company | Trial completion date: Nov 2026 --> Mar 2041 | Trial primary completion date: Nov 2026 --> Mar 2041
    Trial completion date • Trial primary completion date
    |
    Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • KITE-222 • KITE-363 • KITE-439 • KITE-585 • KITE-718
    over2years
    Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, Kite, A Gilead Company | Trial completion date: Mar 2022 --> Oct 2022
    Trial completion date
    |
    HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1)
    |
    cyclophosphamide • fludarabine IV • KITE-718